

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Monday, August 11, 2025

How to Use this Report:

1. Check your genomic testing report (e.g., TEMPUS, FoundationOne, Caris, etc.) to see if your tumor has one of the genomic alterations listed in the left-hand column.

Note: If you are not sure if you have had genomic testing on your tumor, please contact your oncologist.

2. Determine whether any of your genomic alterations are listed in the left-hand column.

3. Review the right-hand column to determine if your type of cancer is listed beside it.

4. A patient may be eligible for more than one genomic alteration and cancer type combination. Please review this report in its entirety.

5. A patient must be deemed eligible based on general and drug specific eligibility criteria reviewed during screening procedures.

6. Contact a TAPUR Study clinical site for more information by visiting TAPUR.org/map which will help you to find the location closest to you.

PLEASE NOTE: This report updates daily. A match appearing on this list does not guarantee it will be available once screening procedures have been completed.

Drug=Abemaciclib (VERZENIO)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CCNE1 amplification	Esophagus Cancer
CDK4 amplification	Any solid tumor
CDK6 amplification	Any solid tumor
CDKN2A loss or mutation	Any solid tumor

Drug=Atezolizumab (TECENTRIQ) + Talazoparib (TALZENNA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
Positive genomic instability (GI) score or genomic loss of heterozygosity (LOH) score above threshold	Any solid tumor except Colorectal cancer

Drug=Futibatinib (LYTG001)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR1 fusion, rearrangement, or mutation	Lung Cancer
	Malignant carcinoid tumors of other site
	Nervous System Cancer
	Pancreatic Cancer

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Monday, August 11, 2025

Drug=Futibatinib (LYTGOBI)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR2 fusion, rearrangement, or mutation	Bone and Cartilage Cancer
	Breast Cancer
	Head and Neck Cancer
	Malignant neoplasm without specification of site
	Ovarian Cancer
	Pancreatic Cancer
	Soft tissue sarcoma
	Squamous cell carcinoma
	Uterine Cancer
FGFR3 fusion, rearrangement, or mutation	Bone and Cartilage Cancer
	Cervical Cancer
	Colorectal cancer
	Esophagus Cancer
	Head and Neck Cancer
	Lung Cancer
	Ovarian Cancer
	Stomach Cancer
	Uterine Cancer

Drug=Palbociclib (IBRANCE)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CDKN2A loss or mutation	Bone and Cartilage Cancer

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Monday, August 11, 2025

Drug=Regorafenib (STIVARGA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
BRAF mutation or amplification	Lung Cancer
KIT mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma
RAF-1 mutation or amplification	Any solid tumor except Colorectal cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma

Drug=Sunitinib (SUTENT)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
FGFR1 mutation or amplification	Colorectal cancer
FGFR2 mutation or amplification	Cancer of Gallbladder and Bile Ducts
FGFR3 mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
KIT mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
PDGFRA mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET
VEGFR2 (KDR) mutation or amplification	Any solid tumor except Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumor (GIST), Pancreatic Neuroendocrine Tumors pNET

Drug=Talazoparib (TALZENNA)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
CHEK2 mutation	Any solid tumor
PALB2 mutation	Any solid tumor except Breast Cancer, Prostate Cancer

Report of Genomic Alteration and Cancer Type Combinations Eligible for TAPUR Study as of Monday, August 11, 2025

Drug=Temsirolimus (TORISEL)

Genomic Alterations that are Eligible for the TAPUR Study	Cancer Type
TSC1 mutation	Any solid tumor except Renal Cell Carcinoma (RCC)
TSC2 mutation	Any solid tumor except Renal Cell Carcinoma (RCC)